Bio-Rad and Sanofi agree bid:
This article was originally published in Clinica
Sanofi-Synthelabo has reached agreement with Bio-Rad to sell its diagnostics division. Hercules, California-based Bio-Rad made a firm offer of $210 million, or one times the previous year's sales, for the Pasteur Sanofi business last month (see Clinica No 863, p 9).
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.